Literature DB >> 31068264

Current Practice Preferences and Safety Protocols for Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents.

Joshua H Uhr1, David Xu1, Ehsan Rahimy2, Jason Hsu3.   

Abstract

PURPOSE: To assess current practice preferences and safety measures used for intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) medications and to assess the variability of practice patterns between academic and nonacademic and between early- and later-career ophthalmologists.
DESIGN: Cross-sectional survey. PARTICIPANTS: Practicing retina specialists who administer intravitreal anti-VEGF injections from the membership pool of the American Society of Retina Specialists.
METHODS: Participants were contacted by e-mail to participate in an anonymous 31-question survey on a common online platform, SurveyMonkey. MAIN OUTCOME MEASURES: Preferred practices for various aspects of administering IVIs and adherence to the most recently published guidelines on IVI techniques.
RESULTS: Preinjection antibiotic drops were used always or often by 10.9% (43/396) of participants. Antibiotics after injection were used always or often by 16.6% (66/398) of participants. Longer (>15 years) compared with shorter (0-15 years) duration of practice was associated with always or often instilling preinjection antibiotics (13.7% vs. 6.7%; P = 0.028), scrubbing eyelids or lashes with antiseptic (43.6% vs. 30.5%; P = 0.008), and being less likely to instill antiseptic immediately before injection (89.7% vs. 95.7%; P = 0.029). Practicing for more than 25 years was associated with always or often instilling antibiotics after injection (22.5% vs. 13.3%; P = 0.017). Academic compared with nonacademic providers were more likely to wear a cap (16.3% vs. 6.8%; P = 0.006), mask (43.0% vs. 29.9%; P = 0.022), and gloves (64.0% vs. 52.1%; P = 0.050) and to drape the patient (17.4% vs. 9.1%; P = 0.027).
CONCLUSIONS: Techniques for IVIs vary widely. Use of periprocedure antibiotics has declined, consistent with new evidence demonstrating lack of efficacy in endophthalmitis prevention as well as their potential harm. However, later-career physicians were more likely to continue to use antibiotics and other techniques advised against in the most recent recommendations of expert consensus groups in the United States and Europe. Academic practitioners were more likely to use protective wear during the procedure.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31068264     DOI: 10.1016/j.oret.2019.03.013

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  5 in total

1.  The Impact of Physician Face Mask Use on Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Samir N Patel; Jason Hsu; Meera D Sivalingam; Allen Chiang; Richard S Kaiser; Sonia Mehta; Carl H Park; Carl D Regillo; Arunan Sivalingam; James F Vander; Allen C Ho; Sunir J Garg
Journal:  Am J Ophthalmol       Date:  2020-09-02       Impact factor: 5.258

2.  Survey of Intravitreal Injection Techniques Among Retina Specialists in Mexico.

Authors:  Andree Henaine-Berra; Vanesa Flores-Peredo; Gabriela Lopezcarasa-Hernandez; Maria Ana Martinez-Castellanos; Ximena Mira-Lorenzo; Adriana Solis-Vivanco; Gerardo Garcia-Aguirre
Journal:  Clin Ophthalmol       Date:  2020-11-26

3.  Survey of Intravitreal Injection Techniques and Treatment Protocols Among Members of the Turkish Ophthalmological Association.

Authors:  Ecem Önder Tokuç; V Levent Karabaş; Figen Şermet
Journal:  Turk J Ophthalmol       Date:  2021-12-28

4.  Reducing Injection-Related Safety Events in Retina Clinics.

Authors:  Denise A John; Beth Hansemann; Philip Lieu; Jennifer Weizer
Journal:  Clin Ophthalmol       Date:  2022-04-22

5.  Autofluorescence indexes as biomarkers for antiangiogenic loading dose outcome in diabetic macular edema.

Authors:  Sergio E Hernández Da Mota; Francisco Béjar Cornejo; Marcela Esquivel Velázquez; Virgilio Lima Gómez; Gerardo González Saldívar; Ernesto Rodríguez Ayala; Raul Vélez-Montoya
Journal:  Ther Adv Ophthalmol       Date:  2020-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.